Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aethlon Medical ( (AEMD) ) has shared an announcement.
On September 4, 2025, Aethlon Medical, Inc. entered into a Securities Purchase Agreement with investors to conduct a public offering, resulting in gross proceeds of $4.5 million. The offering, which closed on September 5, 2025, involved the sale of common stock and warrants, with Maxim Group LLC acting as the exclusive placement agent. The net proceeds of approximately $3.9 million are intended for general corporate purposes, including clinical trial expenses and research and development. The company has agreed to certain restrictions on issuing additional securities for a specified period following the offering, and its officers and directors have entered into lock-up agreements to not sell or transfer company securities for sixty days post-closing.
The most recent analyst rating on (AEMD) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Aethlon Medical stock, see the AEMD Stock Forecast page.
Spark’s Take on AEMD Stock
According to Spark, TipRanks’ AI Analyst, AEMD is a Underperform.
Aethlon Medical’s overall stock score is low due to significant financial challenges, including persistent losses and cash flow issues. The technical indicators suggest negative momentum, and the valuation is unattractive given the negative P/E ratio and lack of dividends. While the earnings call presented some positive strategic efforts, such as cost reduction and trial advancements, the hurdles in clinical trials and financial constraints weigh heavily on the stock’s outlook.
To see Spark’s full report on AEMD stock, click here.
More about Aethlon Medical
Aethlon Medical, Inc. is a clinical-stage medical device company based in San Diego, California. The company is focused on developing the Hemopurifier, a novel platform designed to selectively remove pathogenic targets from biological fluids to address unmet needs in oncology and infectious diseases.
Average Trading Volume: 3,041,046
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.88M
Find detailed analytics on AEMD stock on TipRanks’ Stock Analysis page.